Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET
- PMID: 17987065
- PMCID: PMC3696501
- DOI: 10.1038/sj.npp.1301528
Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET
Abstract
Tourette syndrome (TS) is a neuropsychiatric disorder with childhood onset characterized by motor and phonic tics. Obsessive-compulsive disorder (OCD) is often concomitant with TS. Dysfunctional tonic and phasic dopamine (DA) and serotonin (5-HT) metabolism may play a role in the pathophysiology of TS. We simultaneously measured the density, affinity, and brain distribution of dopamine D2 receptors (D2-R's), dopamine transporter binding potential (BP), and amphetamine-induced dopamine release (DA(rel)) in 14 adults with TS and 10 normal adult controls. We also measured the brain distribution and BP of serotonin 5-HT2A receptors (5-HT2AR), and serotonin transporter (SERT) BP, in 11 subjects with TS and 10 normal control subjects. As compared with controls, DA rel was significantly increased in the ventral striatum among subjects with TS. Adults with TS+OCD exhibited a significant D(2)-R increase in left ventral striatum. SERT BP in midbrain and caudate/putamen was significantly increased in adults with TS (TS+OCD and TS-OCD). In three subjects with TS+OCD, in whom D2-R, 5-HT2AR, and SERT were measured within a 12-month period, there was a weakly significant elevation of DA rel and 5-HT2A BP, when compared with TS-OCD subjects and normal controls. The current study confirms, with a larger sample size and higher resolution PET scanning, our earlier report that elevated DA rel is a primary defect in TS. The finding of decreased SERT BP, and the possible elevation in 5-HT2AR in individuals with TS who had increased DA rel, suggest a condition of increased phasic DA rel modulated by low 5-HT in concomitant OCD.
Figures
References
-
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4. American Psychiatric Association; Washington, DC: 2004. text revision (DSM-IV-TM™)
-
- Baumann MH, Danos P, Krell D, Diekmann S, Leschinger A, Stauch R, et al. Reduced volume of limbic system-affiliated basal ganglia in mood disorders: preliminary data from a postmortem study. Journal of Neuropsychiatry & Clinical Neuroscience. 1999;11:71–78. - PubMed
-
- Brasic JR, Musachio JL, Zhou Y, Cascella N, Nestadt G, Osman M. Neuropsychiatric assessment of [123I]iodo-3-(2 azetidinylmethoxy)pyridine. Movement Disorders. 2001a;16(Suppl 1):S54. [abstract]
-
- Brasic JR, Wong D, Eroglu A. PET scanning in autism spectrum disorders. eMedicine Journal. 2006b;7(2)
-
- Bruun RD, Budman CL. Risperidone as a treatment for Tourette’s syndrome. Journal of Clinical Psychiatry. 1996;57:29–31. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
